Whoop opens blood-testing service to what it says is a 350,000-person waitlist

Whoop has launched Whoop Advanced Labs, a new subscription service that integrates Quest Diagnostics blood tests with its continuous biometric data to offer personalized wellness advice. Priced from $199 to $599 annually, in addition to the existing Whoop membership, the service garnered significant interest with 350,000 individuals on its waiting list. This strategic expansion positions Whoop deeper into the burgeoning direct-to-consumer preventative health market, leveraging its platform to potentially increase average revenue per user and capitalize on the growing demand for comprehensive, personalized health data solutions.

Analysis

Whoop has officially launched its Whoop Advanced Labs service, a strategic expansion into the personalized preventative health market. The service integrates blood tests from Quest Diagnostics (DGX) with its wearable's biometric data, creating a new, tiered subscription revenue stream priced between $199 and $599 annually, on top of its existing hardware membership. The most significant indicator of potential success is the pre-launch waitlist of 350,000 individuals, signaling strong market validation and consumer demand for more comprehensive health insights. This move positions Whoop to substantially increase its average revenue per user (ARPU) by upselling its engaged user base. For Quest Diagnostics, this partnership opens a valuable B2B2C channel to a large, health-conscious demographic, representing an incremental but positive revenue driver. Whoop's pricing places it in a competitive mid-market position, more accessible than ultra-premium offerings like Fountain Life (over $20,000/year) but broader in scope than some lower-cost alternatives, capitalizing on a growing trend of consumer-directed wellness spending.

Key Decisions for Investors

• For investors in Quest Diagnostics (DGX), this partnership is a modest positive catalyst, validating its strategy of expanding into higher-margin, direct-to-consumer wellness channels and should be viewed as a source of incremental growth.
• The strong pre-launch demand for Whoop's service underscores robust growth in the consumer-driven preventative health and wellness technology sectors, warranting closer monitoring of other companies, both public and private, in the at-home diagnostics and personalized health space.
• Investors should watch for data on the conversion rate from Whoop's waitlist to paid subscriptions and long-term retention, as these metrics will be key indicators of the true market size for integrated wellness services and the ultimate financial benefit for partners like DGX.